CAZ/AVI — Competitive Intelligence Brief

CAZ/AVI (CAZ/AVI) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Beta-lactam/beta-lactamase inhibitor combination. Area: Infectious Disease.

marketed Beta-lactam/beta-lactamase inhibitor combination Bacterial penicillin-binding proteins (PBPs); serine beta-lactamases Infectious Disease Small molecule

Target snapshot

CAZ/AVI (CAZ/AVI) — The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School. CAZ/AVI is a combination of ceftazidime (a third-generation cephalosporin) and avibactam (a beta-lactamase inhibitor) that works together to overcome bacterial resistance and kill susceptible gram-negative and gram-positive bacteria.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
CAZ/AVI TARGET	CAZ/AVI	The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School	marketed	Beta-lactam/beta-lactamase inhibitor combination	Bacterial penicillin-binding proteins (PBPs); serine beta-lactamases
Levofloxacin-Amox/clav.	Levofloxacin-Amox/clav.	Buddhist Tzu Chi General Hospital	marketed	Fluoroquinolone + Beta-lactam/Beta-lactamase inhibitor combination	Bacterial DNA gyrase, topoisomerase IV, penicillin-binding proteins
Continuos ceftazidime/avibactam infusion	Continuos ceftazidime/avibactam infusion	Ivan Šitum, MD	marketed	Beta-lactam/beta-lactamase inhibitor combination	Penicillin-binding proteins (PBPs); serine beta-lactamases
treatment with CAZ-AVI	treatment with CAZ-AVI	Southeast University, China	marketed	Beta-lactam/beta-lactamase inhibitor combination	Bacterial penicillin-binding proteins and serine beta-lactamases
Ceftazidime-avibactam + Sulbactam	Ceftazidime-avibactam + Sulbactam	National University of Singapore	marketed	Beta-lactam/beta-lactamase inhibitor combination	Bacterial penicillin-binding proteins (PBPs); serine beta-lactamases
Piperacillin/Tazobactam Continuous infusion	Piperacillin/Tazobactam Continuous infusion	Ain Shams University	marketed	Beta-lactam/beta-lactamase inhibitor combination	Penicillin-binding proteins (PBPs); beta-lactamases
Piperacillin/Tazobactam Intermittent infusion	Piperacillin/Tazobactam Intermittent infusion	Ain Shams University	marketed	Beta-lactam/beta-lactamase inhibitor combination	Penicillin-binding proteins (PBPs); bacterial beta-lactamases

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Beta-lactam/beta-lactamase inhibitor combination class)

1. National University of Singapore · 2 drugs in this class
2. Ain Shams University · 2 drugs in this class
3. Merck Sharp & Dohme LLC · 1 drug in this class
4. Qilu Pharmaceutical Co., Ltd. · 1 drug in this class
5. Southeast University, China · 1 drug in this class
6. The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School · 1 drug in this class
7. Wockhardt · 1 drug in this class
8. Ivan Šitum, MD · 1 drug in this class